Tennessee Attorney General Herbert H. Slatery III recently announced a settlement by 48 states and the District of Columbia with C.R. Bard Inc. and its parent company Becton, Dickinson and Company requiring payment of $60 million for the deceptive marketing of transvaginal surgical mesh devices.

Surgical mesh is a synthetic material implanted to support the pelvic organs of women who suffer from stress urinary incontinence or pelvic organ prolapse. These are common conditions faced by women due to a weakening in their pelvic floor muscles caused by childbirth, age, and other factors.

Thousands of women implanted with surgical mesh have made claims that they suffered serious complications resulting from these devices.

The attorneys general allege that C.R. Bard misrepresented or failed to adequately disclose serious and life-altering risks of surgical mesh devices, such as chronic pain, scarring and shrinking of bodily tissue, painful sexual relations, and recurring infections, among other complications.

“Patients should be fully informed about the serious risks associated with these devices and this settlement will require that,” said General Slatery.

C.R. Bard and its parent company, Becton, Dickinson and Company, have agreed to pay $60 million to the 48 participating states and the District of Columbia. Although C.R. Bard stopped selling transvaginal mesh, the settlement provides injunctive relief, requiring both C.R. Bard and Becton, Dickinson and Company to adhere to certain injunctive terms if they reenter the transvaginal mesh market.

Tennessee will receive $1,114,246.00 under the settlement.

Under the terms of the settlement, the companies are required to:

•Provide patients with understandable descriptions of complications in marketing materials.

•Include a list of certain complications in all marketing materials that address complications.

•Disclose complications related to the use of mesh in any training provided that includes risk information.

•Disclose sponsorship in clinical studies, clinical data, or preclinical data for publication.

•Refrain from citing to any clinical study, clinical data, or preclinical data regarding mesh, for which the company has not complied with the disclosure requirements.

•Require consultants to agree to disclose in any public presentation or submission for publication Bard’s sponsorship of the contracted for activity.

•Register all Bard-sponsored clinical studies regarding mesh with ClinicalTrials.gov.

•Train independent contractors, agents, and employees who sell, market, or promote mesh, regarding their obligations to report all patient complaints and adverse events to the company.

•Ensure that its practices regarding the reporting of patient complaints are consistent with FDA requirements.

To read the Complaint and Consent Judgment visit https://www.tn.gov/content/dam/tn/attorneygeneral/documents/pr/2020/pr20-37-complaint.pdf.

Joining Tennessee in this multistate settlement are Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Texas, Utah, Vermont, Virginia, Washington, and Wisconsin.